ENTRY       D11127                      Drug
NAME        Tibulizumab (USAN/INN)
FORMULA     C8934H13698N2398O2808S56
EXACT_MASS  201296.715
MOL_WEIGHT  201420.3777
SEQUENCE    (Heavy chain)
            QVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQP PGKGLEWIGE INHSGSTNYN
            PSLKSRVTIS VDTSKNQFSL KLSSVTAADT AVYYCARGYY DILTGYYYYF DYWGQGTLVT
            VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL
            QSSGLYSLSS VVTVPSSSLG TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG
            PSVFLFPPKP KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN
            STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE
            MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SRLTVDKSRW
            QEGNVFSCSV MHEALHNHYT QKSLSLSPGG GGSGGGGTGG GGSQVQLVQS GAEVKKPGSS
            VKVSCKASGY KFTDYHIHWV RQAPGQCLEW MGVINPTYGT TDYNQRFKGR VTITADESTS
            TAYMELSSLR SEDTAVYYCA RYDYFTGTGV YWGQGTLVTV SSGGGGSGGG GSGGGGSGGG
            GSDIVMTQTP LSLSVTPGQP ASISCRSSRS LVHSRGETYL HWYLQKPGQS PQLLIYKVSN
            RFIGVPDRFS GSGSGTDFTL KISRVEAEDV GVYYCSQSTH LPFTFGCGTK LEIK
            (Light chain)
            EIVLTQSPAT LSLSPGERAT LSCRASQSVS RYLAWYQQKP GQAPRLLIYD ASNRATGIPA
            RFSGSGSGTD STLTISSLEP EDFAVYYCQQ RSNWPRTFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 1DNALQSGNSQ ESVTEQDSKD
            STYSLSNTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H95, H137-L214, H150-H206, H229-H'229, H232-H'232, H264-H324, H370-H428, H485-H559, H507-H707, H625-H695, H'22-H'95, H'137-L'214, H'150-H'206, H'264-H'324, H'370-H'428, H'485-H'559, H'507-H'707, H'625-H'695, L23-L88, L134-L194, L'23-L'194)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
EFFICACY    Immunomodulator
  TYPE      Monoclonal antibody, bispecific antibody
COMMENT     Treatment of autoimmune disorders
TARGET      TNFSF13B (BAFF, CD257) [HSA:10673] [KO:K05476]
            IL17A [HSA:3605] [KO:K05489]
  PATHWAY   hsa04060(10673+3605)  Cytokine-cytokine receptor interaction
            hsa04064(10673)  NF-kappa B signaling pathway
            hsa04657(3605)  IL-17 signaling pathway
BRITE       Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D11127  Tibulizumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interleukins
                IL17A
                 D11127  Tibulizumab (USAN/INN)
               Tumor necrosis factors
                TNFSF13B (BAFF, CD257)
                 D11127  Tibulizumab (USAN/INN)
DBLINKS     CAS: 1849636-24-3
            PubChem: 376219051
///
